Federal Register / Vol. 88, No. 221 / Friday, November 17, 2023 / Notices 80323 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W104, 

Rockville, Maryland 20850, 240–276–6351, 

david.ransom@nih.gov. 

Name of Committee: National Cancer 

Institute Initial Review Group, Transition to 

Independence Study Section (I). 

Date: February 15–16, 2024. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W602 Rockville, Maryland 20850, (Virtual 

Meeting). 

Contact Person: Delia Tang, M.D., 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W602, Rockville, Maryland 20850, 

240–276–6456. tangd@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, SEP–10: 

NCI Clinical and Translational Cancer 

Research. 

Date: February 22–23, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W606, Rockville, Maryland 20850, (Virtual 

Meeting). 

Contact Person: Bruce Daniel Hissong, 

Ph.D., Scientific Review Officer, Resource 

and Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W606 Rockville, Maryland 20850, 

240–276–7752. bruce.hissong@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: November 14, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–25490 Filed 11–16–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Notice of Meeting; Correction 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice; correction. 

SUMMARY: The Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) published a document in the 

Federal Register of October 17, 2023, in 

FR Doc. 2023–22797 announcing the 

meeting of the SAMHSA Center for 

Substance Abuse Prevention (CSAP) 

Drug Testing Advisory Board (DTAB) on 

December 5, 2023, and to request 

comments on editing the Authorized 

Drug Testing Panels for federally 

regulated testing. The document was 

revised to reflect new information under 

the Supplementary Section. 

FOR FURTHER INFORMATION CONTACT: Lisa 

Davis, Division of Workplace Programs, 

SAMHSA/CSAP, 5600 Fishers Lane, 

Rockville, MD 20857, (240) 276–1440 

(voice), Lisa.Davis@samhsa.hhs.gov 

(email). 

SUPPLEMENTARY INFORMATION: 

Notice of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given that the 

Substance Abuse and Mental Health 

Services Administration’s (SAMHSA) 

Center for Substance Abuse Prevention’s 

(CSAP) Drug Testing Advisory Board 

(DTAB) will convene via web 

conference on December 5, 2023, from 

10:00 a.m. EST to 4:30 p.m. 

The board will meet in open-session 

December 5, 2023, from 10:00 a.m. EST 

to 4:30 p.m. EST to hear Federal Partner 

updates and presentations regarding 

National Laboratory Certification 

Program (NLCP) activities, updates to 

the Medical Review Officer (MRO) 

Guidance Manual, laboratory-created 

cannabinoids and other contaminants in 

commercially available products, and 

the process for adding or removing 

analytes from the Authorized Drug 

Testing Panels for federally regulated 

testing. The Board will discuss the 

Mandatory Guidelines for Federal 

Workplace Drug Testing Programs and 

revisions to the Authorized Drug 

Testing Panels for Urine and Oral Fluid 

to add fentanyl and (for urine) norfentanyl, and to remove 

methylenedioxymethamphetamine 

(MDMA) and 

methylenedioxyamphetamine (MDA). 

Additionally, the Department is asking 

for public comments on these 

recommended changes to the drug 

testing panel. 

Section 8105 of the Fighting Opioid 

Abuse in Transportation Act, included 

in the SUPPORT for Patients and 

Communities Act, required the 

Secretary to determine whether it is 

justified, based on the reliability and 

cost-effectiveness of testing, to revise 

the Mandatory Guidelines for Federal 

Workplace Drug Testing Programs to 

include fentanyl. Section 8105 

additionally required the Secretary to 

consider whether to include any other 

drugs or other substances listed in 

Schedule I and II of Controlled 

Substances Act (CSA). Norfentanyl is a 

metabolite of fentanyl. Because it is also 

an immediate precursor used in the 

illicit manufacture of fentanyl, it is a 

Schedule II substance under the CSA. 

Fentanyl accounts for a large 

proportion of overdose deaths in the 

United States and is therefore an 

important public safety concern. 

Furthermore, fentanyl is increasingly 

used as a stand-alone substance of 

abuse, not in conjunction with heroin 

and other substances. According to the 

National Forensic Laboratory 

Information System (NFLIS) 2021 

report, fentanyl was the 4th most 

frequently identified drug and 

accounted for 11.61% of all drugs 

reported by forensic laboratories.1

Norfentanyl is an important component 

of identifying fentanyl users when urine 

is the specimen matrix. Fentanyl has 

been detected in oral fluid in pain 

management patients, overdose cases, 

and driving under the influence of drugs 

(DUID) cases. Information provided by 

HHS-certified laboratories in 2023 

indicated that a majority (84%) of the 

laboratories analyzed non-regulated 

workplace specimens for fentanyl and/ 

or norfentanyl, and that all had the 

ability to analyze urine specimens for 

fentanyl with sufficiently sensitive 

detection limits using commercially 

available immunoassay kits and 

confirmatory test instrumentation 

commonly used in HHS-certified 

laboratories. 

The Division of Workplace Programs 

welcomes public comment prior to the 

DTAB meeting regarding the possible 

addition of fentanyl to the Authorized 

Drug Testing Panels for Urine and Oral 

Fluid. Please see below for the process 

to submit comments. 

Addition to HHS Drug Testing Panels 

as listed below: 

Urine analyte Initial test 

cutoff 

Confirmation 

cutoff 

Fentanyl ............ 1 ng/mL ...... 0.5 ng/mL. 

Norfentanyl ....... 1 ng/mL ...... 0.5 ng/mL. 

Oral fluid 

analyte 

Initial test 

cutoff 

Confirmation 

cutoff 

Fentanyl ............ 1 ng/mL ...... 0.5 ng/mL. 

Remove Methylenedioxyamphetamine 

(MDA) and 

Methylenedioxymethamphetamine 

(MDMA) from the Authorized Drug 

Testing Panel: 

The Department plans to remove 

MDA and 


khammond on DSKJM1Z7X2PROD with NOTICES
80324 Federal Register / Vol. 88, No. 221 / Friday, November 17, 2023 / Notices 

methylenedioxymethamphetamine from 

the drug testing panel, because the 

number of positive specimens reported 

by HHS-certified laboratories does not 

support testing all specimens for MDA 

and MDMA in Federal workplace drug 

testing programs. Information provided 

to the Department through the NLCP in 

2021 and 2022 shows the positivity rate 

for MDMA ranges from 0.001 to 0.003%, 

and a review of the results indicate that 

>25% of the positive specimens are 

likely agency blind samples. MDA has 

a lower positivity rate than MDMA and 

both have lower positivity rates than 

phencyclidine (PCP). SAMHSA also 

considered removing PCP but decided 

against this change. While PCP has an 

overall positivity rate nearly as low as 

MDMA, there are regional differences in 

positivity, with some areas of the 

country having much higher rates, so 

PCP remains a regulated test analyte. 

Because MDA and MDMA are Schedule 

I drugs, a Federal agency may test 

specimens for these analytes in 

accordance with Section 3.2 of the 

UrMG and OFMG (i.e., on a case-by-case 

basis for reasonable suspicion or postaccident testing, or routinely with a 

waiver from the Secretary). The Division 

of Workplace Programs welcomes 

public comment prior to the DTAB 

meeting regarding the removal of MDA 

and MDMA from the Urine and Oral 

Fluid Analyte Table. Please see below 

for the process to submit comments. 

Meeting registration information can 

be completed at https://snacregister.

samhsa.gov/. Web conference and call 

information will be sent after 

completing registration. Meeting 

information and a roster of DTAB 

members may be obtained by accessing 

the SAMHSA Advisory Committees 

website, https://www.samhsa.gov/ 

about-us/advisory-councils/meetings, or 

by contacting the Designated Federal 

Officer, Lisa Davis. 

Committee Name: Substance Abuse 

and Mental Health Services 

Administration, Center for Substance 

Abuse Prevention, Drug Testing 

Advisory Board. 

Dates/Time/Type: December 5, 2023, 

from 10:00 a.m. EST to 4:30 p.m. EST: 

OPEN 

Place: Virtual. 

To Submit Comments: Requests to 

make public comment during the public 

comment period of the December DTAB 

meeting must be made in writing at least 

7 days prior to the meeting to the 

following email: DFWP@

samhsa.hhs.gov. 

Please submit written comments 

regarding the addition of Fentanyl and 

the removal of MDA and MDMA to the 

analyte table to the following email: 

DFWP@samhsa.hhs.gov. 

Comments regarding the addition of 

Fentanyl and the removal of MDA and 

MDMA to the analyte table will be 

accepted for review for an additional 30 

days following this meeting, or no later 

than January 4th, 2024. 

Contact: Lisa S. Davis, M.S., Social 

Science Analyst, Center for Substance 

Abuse Prevention, 5600 Fishers Lane, 

Rockville, Maryland 20857, Telephone: 

(240) 276–1440, email: Lisa.Davis@

samhsa.hhs.gov. 

Endnote: 

1National Forensic Laboratory Information 

System (NFLIS). (2021). NFLIS-Drug 2021 

Annual Report. U.S. Department of Justice, 

Drug Enforcement Agency, Diversion Control 

Division. https://www.nflis.deadiversion.

usdoj.gov/. 

Dated: November 13, 2023. 

Anastasia Flanagan, 

Public Health Advisor, Division of Workplace 

Programs. 

[FR Doc. 2023–25463 Filed 11–16–23; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID: FEMA–2023–0030; OMB No. 

1660–0125] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request; FEMA 

Preparedness Grants: Homeland 

Security Grant Program (HSGP) 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: 60-Day notice of revision and 

request for comments. 

SUMMARY: The Federal Emergency 

Management Agency (FEMA), as part of 

its continuing effort to reduce 

paperwork and respondent burden, 

invites the general public to take this 

opportunity to comment on a revision of 

a currently approved information 

collection. In accordance with the 

Paperwork Reduction Act of 1995, this 

notice seeks comments concerning the 

Homeland Security Grant Program 

(HSGP), which includes the State 

Homeland Security Program (SHSP), the 

Urban Area Security Initiative (UASI), 

and Operation Stonegarden (OPSG). 

This revision removes the OPSG Daily 

Activity Report (FEMA Form FF–207– 

FY–21–113 (formerly 089–0–27)) from 

the collection. 

DATES: Comments must be submitted on 

or before January 16, 2024. 

ADDRESSES: To avoid duplicate 

submissions to the docket, please 

submit comments at 

www.regulations.gov under Docket ID 

FEMA–2023–0030. Follow the 

instructions for submitting comments. 

All submissions received must 

include the agency name and Docket ID. 

Regardless of the method used for 

submitting comments or material, all 

submissions will be posted, without 

change, to the Federal eRulemaking 

Portal at http://www.regulations.gov, 

and will include any personal 

information you provide. Therefore, 

submitting this information makes it 

public. You may wish to read the 

Privacy and Security Notice that is 

available via a link on the homepage of 

www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Alexander Mrazik Jr., Branch Chief, 

FEMA’s Grant Programs Directorate, 

Grant Operations Division, 

Preparedness Grants Division, 

Homeland Security Programs Branch, at 

(202) 786–9732 or Alexander.MrazikJr@

fema.dhs.gov. You may contact the 

Information Management Division for 

copies of the proposed collection of 

information at email address: FEMAInformation-Collections-Management@

fema.dhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Federal Emergency Management 

Agency’s (FEMA’s) Homeland Security 

Grant Program (HSGP) supports state 

and local efforts to prevent terrorism 

and other catastrophic events and to 

prepare the Nation for the threats and 

hazards that pose the greatest risk to the 

security of the United States. The HSGP 

provides funding to implement 

investments that build, sustain, and 

deliver the 32 core capabilities essential 

to achieving the National Preparedness 

Goal of a secure and resilient Nation. 

The building, sustainment, and delivery 

of these core capabilities are not 

exclusive to any single level of 

government, organization, or 

community, but rather, require the 

combined effort of the whole 

community. The HSGP supports core 

capabilities across the five mission areas 

of Prevention, Protection, Mitigation, 

Response, and Recovery based on 

allowable costs. HSGP is comprised of 

three grant programs: State Homeland 

Security Program (SHSP), Urban Area 

Security Initiative (UASI), and 

Operation Stonegarden (OPSG). 

Together, these grant programs fund a 

range of activities, including planning, 

organization, equipment purchase, 

training, exercises, and management 


khammond on DSKJM1Z7X2PROD with NOTICES